Intriguingly, although IFN-Is from DCs provided a dominant anti-tumor role after RT [36], IFN-Is in cancer cells actually protected them from CD8+ T cell-mediated killing after RT by inducing serpinb9, a physiological inhibitor of GzmB. The gene discussed is IFNA1; the disease is cancer.